Abstract
Therapy-related myeloid neoplasms (t-MN) are a late complication of the successful use of cytotoxic therapy for patients with cancer. A heterozygous deletions of the long arm of chromosome 5 [del(5q)], observed in 40% of patients, is associated with prior exposure to alkylating agents, and a high frequency of TP53 loss or mutation. In previous studies, we demonstrated that haploinsufficiency of 2 del(5q) genes, Egr1, and Apc, individually play a role in the pathogenesis of hematologic disease in mice. We now show that loss of one copy of Egr1 or Tp53 in an Apc haploinsufficient background (Apc del/+) accelerated the development of a macrocytic anemia with monocytosis, early features of t-MN. The development of anemia was significantly accelerated by treatment of mice with the alkylating agent, N-ethyl-N-nitrosourea (ENU), regardless of the levels of expression of Egr1 and Tp53. Transplantation of either wild type; Egr1+/-; Tp53 +/-; Apcdel/+; or Egr1+/-, Apcdel/+ bone marrow cells into lethally irradiated Apcdel/+ recipients resulted inrapid development of anemia that was further accelerated by administration of ENU to recipients, demonstrating that the Apc del/+-induced anemia was cell extrinsic and potentiated by ENU mutagenesis. These data emphasize the synergistic role of cell intrinsic and cell extrinsic (microenvironment) factors in the pathogenesis of t-MN, and raise awareness of the deleterious effects of cytotoxic therapy on the stromal microenvironment. © 2014 by The American Society of Hematology.
Cite
CITATION STYLE
Stoddart, A., Wang, J., Fernald, A. A., Karrison, T., Anastasi, J., & Le Beau, M. M. (2014). Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc. Blood, 123(2), 228–238. https://doi.org/10.1182/blood-2013-05-506568
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.